Trial reportAmerican journal of epidemiology2015
Tuberculosis control in South African gold mines: mathematical modeling of a trial of community-wide isoniazid preventive therapy.
Trial report in American journal of epidemiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03537872 (PROvide MIner-friendly SErvices for Integrated TB/HIV Care in Lesotho Study), which is not on this map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
PROvide MIner-friendly SErvices for Integrated TB/HIV Care in Lesotho Study (PROMISE Study)
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Economic and modeling evidence for tuberculosis preventive therapy among people living with HIV: A systematic review and meta-analysis.PLoS medicine · 2021Pooled it
- How radical is radical cure? Site-specific biases in clinical trials underestimate the effect of radical cure on Plasmodium vivax hypnozoites.Malaria journal · 2021Trial
- Monocyte metabolic transcriptional programs associate with resistance to tuberculin skin test/interferon-γ release assay conversion.The Journal of clinical investigation · 2021Trial
- Lansoprazole use and tuberculosis incidence in the United Kingdom Clinical Practice Research Datalink: A population based cohort.PLoS medicine · 2017Trial
- A proteome-wide atlas of humoral immunity toFrontiers in immunology · 2026Article
- Tuberculosis Preventive Treatment in High TB-Burden Settings: A State-of-the-Art Review.Drugs · 2025Review
- Article
- Silicotuberculosis: a critical narrative review.European respiratory review : an official journal of the European Respiratory Society · 2024Review
- Nonlinear growth and mathematical modelling of COVID-19 in some African countries with the Atangana-Baleanu fractional derivative.Communications in nonlinear science & numerical simulation · 2022Article
- Resistance to Mycobacterium tuberculosis infection among highly TB exposed South African gold miners.PloS one · 2022Article
- Durations of asymptomatic, symptomatic, and care-seeking phases of tuberculosis disease with a Bayesian analysis of prevalence survey and notification data.BMC medicine · 2021Article
- Phenotype Definition for "Resisters" toFrontiers in immunology · 2021Review
- The Importance of Heterogeneity to the Epidemiology of Tuberculosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Article
- Projected population-wide impact of antiretroviral therapy-linked isoniazid preventive therapy in a high-burden setting.AIDS (London, England) · 2019Article
- Immunological mechanisms of human resistance to persistent Mycobacterium tuberculosis infection.Nature reviews. Immunology · 2018Review
- Small contribution of gold mines to the ongoing tuberculosis epidemic in South Africa: a modeling-based study.BMC medicine · 2018Article
- Simulations for designing and interpreting intervention trials in infectious diseases.BMC medicine · 2017Article
- Research Roadmap for Tuberculosis Transmission Science: Where Do We Go From Here and How Will We Know When We're There?The Journal of infectious diseases · 2017Review
- Designing and Evaluating Interventions to Halt the Transmission of Tuberculosis.The Journal of infectious diseases · 2017Review
- Tuberculosis Infectiousness and Host Susceptibility.The Journal of infectious diseases · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
A recent major cluster randomized trial of screening, active disease treatment, and mass isoniazid preventive therapy for 9 months during 2006-2011 among South African gold miners showed reduced individual-level tuberculosis incidence but no detectable population-level impact. We fitted a dynamic mathematical model to trial data and explored 1) factors contributing to the lack of population-level impact, 2) the best-achievable impact if all implementation characteristics were increased to the highest level achieved during the trial ("optimized intervention"), and 3) how tuberculosis might be better controlled with additional interventions (improving diagnostics, reducing treatment delay, providing isoniazid preventive therapy continuously to human immunodeficiency virus-positive people, or scaling up antiretroviral treatment coverage) individually and in combination. We found the following: 1) The model suggests that a small proportion of latent infections among human immunodeficiency virus-positive people were cured, which could have been a key factor explaining the lack of detectable population-level impact. 2) The optimized implementation increased impact by only 10%. 3) Implementing additional interventions individually and in combination led to up to 30% and 75% reductions, respectively, in tuberculosis incidence after 10 years. Tuberculosis control requires a combination prevention approach, including health systems strengthening to minimize treatment delay, improving diagnostics, increased antiretroviral treatment coverage, and effective preventive treatment regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.